000 04220naa a22005057i 4500
001 UMUN-OA-20261005-MLS-051
003 local
005 20261005174905.0
006 m o d
007 cr||||||||||||
008 261005s2016 xx o u000 0 eng d
024 7 _a10.1371/journal.pone.0151073
_2doi
035 _a(local)EuropePMC:PMC4783056
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aSamuel G Schumacher
_eauthor.
245 1 0 _aImpact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies. /
_cSamuel G Schumacher; Hojoon Sohn; Zhi Zhen Qin [and others].
264 1 _a[Place of publication not identified] :
_bPLOS,
_c2016.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aBackground Several reviews on the accuracy of Tuberculosis (TB) Nucleic Acid Amplification Tests (NAATs) have been performed but the evidence on their impact on patient-important outcomes has not been systematically reviewed. Given the recent increase in research evaluating such outcomes and the growing list of TB NAATs that will reach the market over the coming years, there is a need to bring together the existing evidence on impact, rather than accuracy. We aimed to assess the approaches that have been employed to measure the impact of TB NAATs on patient-important outcomes in adults with possible pulmonary TB and/or drug-resistant TB. Methods We first develop a conceptual framework to clarify through which mechanisms the improved technical performance of a novel TB test may lead to improved patient outcomes and outline which designs may be used to measure them. We then systematically review the literature on studies attempting to assess the impact of molecular TB diagnostics on such outcomes and provide a narrative synthesis of designs used, outcomes assessed and risk of bias across different study designs. Results We found 25 eligible studies that assessed a wide range of outcomes and utilized a variety of experimental and observational study designs. Many potentially strong design options have never been used. We found that much of the available evidence on patient-important outcomes comes from a small number of settings with particular epidemiological and operational context and that confounding, time trends and incomplete outcome data receive insufficient attention. Conclusions A broader range of designs should be considered when designing studies to assess the impact of TB diagnostics on patient outcomes and more attention needs to be paid to the analysis as concerns about confounding and selection bias become relevant in addition to those on measurement that are of greatest concern in accuracy studies.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttp://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _amolecular diagnostics
655 4 _aReview articles.
700 0 _aHojoon Sohn
_eauthor.
700 0 _aZhi Zhen Qin
_eauthor.
700 0 _aGenevieve Gore
_eauthor.
700 0 _aJ Lucian Davis
_eauthor.
700 0 _aClaudia M Denkinger
_eauthor.
700 0 _aMadhukar Pai
_eauthor.
773 0 _tPloS one
_gVol. 11, no. 3, (2016), pages/article e0151073
_x1932-6203
856 4 0 _uhttps://europepmc.org/articles/PMC4783056
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC4783056
_qlocal
942 _n0
999 _c1193
_d1193